ENTA FY 2015 Earnings Report — Enanta Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

Enanta Pharmaceuticals, Inc.ENTA

FY 2015 Earnings

Reported December 11, 2015

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2015	Prior Q	FY 2014	QoQ Change	YoY Change
Revenue	$161M	—	$48M	—	237.0%
Op. Income	$124M	—	$19M	—	553.9%
Gross Margin	100.0%	—	100.0%	—	0.0pp
Net Margin	49.1%	—	72.1%	—	-23.0pp
EPS (Diluted)	$4.09	—	$1.80	—	127.2%
Free Cash Flow	$74M	—	$19M	—	288.2%

Revenue Flow

Item	Amount
REVENUE	$161M
Cost of Revenue	$0
GROSS PROFIT	$161M
R&D Expenses	$23M
Selling & Marketing	$0
General & Administrative	$14M
SG&A Expenses	$14M
Other Expenses	$0
Operating Expenses	$37M
Cost & Expenses	$37M
OPERATING INCOME	$124M
Interest Income	$968.0K
Interest Expense	$8.0K
Other Income/Expenses	$1M
INCOME BEFORE TAX	$125M
Income Tax Expense	$46M
Net Income from Continuing Ops	$79M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$79M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$79M
D&A	$639.0K
EBIT	$124M
EBITDA	$125M
EPS	$4
EPS Diluted	$4

Income Statement

Item	Amount
REVENUE	$161M
Cost of Revenue	$0
GROSS PROFIT	$161M
R&D Expenses	$23M
Selling & Marketing	$0
General & Administrative	$14M
SG&A Expenses	$14M
Other Expenses	$0
Operating Expenses	$37M
Cost & Expenses	$37M
OPERATING INCOME	$124M
Interest Income	$968.0K
Interest Expense	$8.0K
Other Income/Expenses	$1M
INCOME BEFORE TAX	$125M
Income Tax Expense	$46M
Net Income from Continuing Ops	$79M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$79M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$79M
D&A	$639.0K
EBIT	$124M
EBITDA	$125M
EPS	$4
EPS Diluted	$4

Cash Flow Statement

Item	Amount
Net Income	$79M
Depreciation & Amortization	$639.0K
Stock-Based Compensation	$6M
Deferred Income Tax	$11M
Other Non-Cash Items	-$3M
Change in Working Capital	-$17M
OPERATING CASH FLOW	$77M
Capital Expenditure	-$2M
Acquisitions (Net)	$9.0K
Purchases of Investments	-$196M
Sales/Maturities of Investments	$111M
Other Investing Activities	-$172.0K
NET CASH FROM INVESTING	-$88M
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$3M
NET CASH FROM FINANCING	$3M
FREE CASH FLOW	$74M
Net Change in Cash	-$9M

Balance Sheet

Item	Amount
Cash & Equivalents	$22M
Short-Term Investments	$123M
Net Receivables	$16M
Inventory	$0
Other Current Assets	$10M
TOTAL CURRENT ASSETS	$171M
PP&E (Net)	$6M
Goodwill	$0
Intangible Assets	$0
Long-Term Investments	$64M
Tax Assets	$5M
Other Non-Current Assets	$608.0K
TOTAL NON-CURRENT ASSETS	$75M
TOTAL ASSETS	$246M
Account Payables	$2M
Short-Term Debt	$0
Deferred Revenue	$1M
Other Current Liabilities	$3M
TOTAL CURRENT LIABILITIES	$7M
Long-Term Debt	$0
Deferred Revenue NC	$462.0K
Deferred Tax Liabilities	$448.0K
Other Non-Current Liabilities	$3M
TOTAL NON-CURRENT LIABILITIES	$3M
TOTAL LIABILITIES	$10M
Common Stock	$187.0K
Additional Paid-In Capital	$230M
Retained Earnings	$6M
Treasury Stock	$0
Accum. Other Comp. Income	$33.0K
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$236M
Minority Interest	$0
TOTAL EQUITY	$236M
TOTAL LIABILITIES & EQUITY	$246M
Total Debt	$598.0K
Net Debt	-$21M